ANIP up +3.37% percent Today $ANIP High is at 56.74 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 10:58 AM

ANIP up +3.37% percent Today $ANIP High is at 56.74 and the Low 54.01 with current volume of 81,477.

Recent News posted below.

ANI Pharmaceuticals Inc ANIP other info.
http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/

ANIP ANI Pharmaceuticals Inc Recent Headline News

Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 12 mins ago
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 56.01 (+2.06), AMAG: 34.69 (+0.69), AFFX: 9.45 (-0.26), PBYI: 223.58 (+7.36)

Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 306.96 (+1.53), ANIP: 56.01 (+2.06), AMAG: 34.69 (+0.69), AFFX: 9.45 (-0.26)

Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 56.01 (+2.06), ICPT: 159.47 (-3.11), AMAG: 34.69 (+0.69), AFFX: 9.45 (-0.26)

Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:26AM CST
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 56.01 (+2.06)

ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 56.01 (+2.06), SCMP: 11.94 (+0.64)

Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 56.01 (+2.06)

Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 306.96 (+1.53), ANIP: 56.01 (+2.06), CLDX: 17.90 (+3.74), AMAG: 34.69 (+0.69)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.57 (+0.11), ANIP: 56.01 (+2.06), ACGL: 56.85 (-0.45), ACCO: 8.96 (-0.03), FLWS: 8.84 (-0.15)

ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"

(NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health.
ANIP: 56.01 (+2.06)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 23.37 (-0.61), HBNK: 19.95 (+0.17), ASMI: 41.46 (+0.20), RRGB: 68.69 (+0.18), SAPE: 24.68 (unch), PLUG: 3.72 (unch), ANIP: 56.01 (+2.06), ODP: 6.57 (-0.22), MTEX: 21.98 (+1.67), JAXB: 11.75 (-0.15), ALQA: 5.10 (+0.05), YRCW: 23.46 (-0.27)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 6.13 (+0.05), NEO: 4.69 (+0.01), AU: 9.39 (-0.17), FNHC: 24.57 (-0.16), AMS: 2.53 (-0.19), NYMX: 0.57 (+0.02), AMDA: 1.37 (+0.15), CVD: 100.35 (+0.05), GBIM: 6.50 (+0.20), RCAP: 11.84 (-0.25), KBIO: 1.96 (-0.14), COOL: 0.81 (-0.09), SAPE: 24.68 (unch), XTLB: 2.58 (+0.13), GERN: 3.03 (+0.27), ANIP: 56.01 (+2.06), BBLU: 1.32 (+0.02), NXTD: 2.31 (unch), AP: 18.78 (-0.10), ALQA: 5.10 (+0.05)

ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST

ANIP: 56.01 (+2.06)

ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 56.01 (+2.06)

ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST

ANIP: 56.01 (+2.06)

ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"

(NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014.
ANIP: 56.01 (+2.06)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST

ACW: 4.84 (+0.03), SYY: 38.86 (+0.28), L: 42.55 (-0.23), EEP: 37.93 (+0.59), SNH: 22.21 (+0.03), INN: 11.47 (-0.07), ITG: 19.61 (+0.10), NSP: 32.90 (-0.08), S: 5.01 (-0.04), ALE: 49.97 (+0.14), GVA: 35.92 (-0.35), MCY: 53.86 (-0.19), ARNA: 4.58 (+0.05), CHD: 73.72 (+0.19), ARE: 82.56 (+0.24), USAK: 18.56 (+0.11), BWP: 16.76 (-0.19), KRG: 26.18 (-0.02), CYOU: 22.74 (-1.13), MNKD: 6.22 (+0.06), HNT: 50.87 (+1.07), AMH: 17.24 (-0.03), ARCB: 42.42 (-0.19), ANIP: 56.01 (+2.06), AMG: 195.41 (-1.53), HAE: 36.98 (-0.15), SOHU: 49.42 (-1.54), CNA: 38.94 (-0.18)

ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 107.66 (+0.76), MACK: 8.70 (+0.22), ANIP: 56.01 (+2.06), ILMN: 182.54 (+2.04)

ANI Pharma reports November 3
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:35AM CDT

ANIP: 56.01 (+2.06)

5 Stocks Poised for Big Breakouts
at The Street - Mon Oct 27, 8:32AM CDT
These stocks look ready to break out and trade higher from current levels.
ANIP: 56.01 (+2.06), KTOS: 5.32 (-0.08), BLOX: 17.04 (+0.18), CSLT: 11.17 (-0.69), FPRX: 15.44 (+0.25)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...